126 related articles for article (PubMed ID: 10500834)
1. New developments in the treatment of acute myeloid leukemia.
Smeets M; de Witte T; van der Lely N; Raymakers R; Muus P
Adv Exp Med Biol; 1999; 457():557-65. PubMed ID: 10500834
[TBL] [Abstract][Full Text] [Related]
2. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia.
Hu XF; Slater A; Kantharidis P; Rischin D; Juneja S; Rossi R; Lee G; Parkin JD; Zalcberg JR
Blood; 1999 Jun; 93(12):4086-95. PubMed ID: 10361105
[TBL] [Abstract][Full Text] [Related]
3. Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance.
Smeets ME; Raymakers RA; Vierwinden G; Pennings AH; Wessels H; de Witte T
Blood; 1999 Oct; 94(7):2414-23. PubMed ID: 10498614
[TBL] [Abstract][Full Text] [Related]
4. [The causes of treatment ineffectiveness in acute myelogenous leukemia--the role of blast resistance to cytotoxic drugs].
Machaczka M; Rucińska M; Jabłoński M; Skotnicki AB
Przegl Lek; 1998; 55(7-8):407-13. PubMed ID: 10021886
[TBL] [Abstract][Full Text] [Related]
5. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
6. [Therapy of acute leukemia in the adult. Role of anthracyclines].
Gisselbrecht C; Lepage E; Lenoble M; Marty M; Boiron M
Pathol Biol (Paris); 1987 Jan; 35(1):69-74. PubMed ID: 3550615
[TBL] [Abstract][Full Text] [Related]
7. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).
Advani R; Visani G; Milligan D; Saba H; Tallman M; Rowe JM; Wiernik PH; Ramek J; Dugan K; Lum B; Villena J; Davis E; Paietta E; Litchman M; Covelli A; Sikic B; Greenberg P
Adv Exp Med Biol; 1999; 457():47-56. PubMed ID: 10500779
[TBL] [Abstract][Full Text] [Related]
8. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.
Wattel E; Solary E; Hecquet B; Caillot D; Ifrah N; Brion A; Milpied N; Janvier M; Guerci A; Rochant H; Cordonnier C; Dreyfus F; Veil A; Hoang-Ngoc L; Stoppa AM; Gratecos N; Sadoun A; Tilly H; Brice P; Lioure B; Desablens B; Pignon B; Abgrall JP; Leporrier M; Fenaux P
Adv Exp Med Biol; 1999; 457():35-46. PubMed ID: 10500778
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation.
Wang YH; Imai Y; Shiseki M; Tanaka J; Motoji T
Leuk Res; 2018 Apr; 67():99-108. PubMed ID: 29482174
[TBL] [Abstract][Full Text] [Related]
10. ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients.
Scheiner MA; da Cunha Vasconcelos F; da Matta RR; Dal Bello Figueira R; Maia RC
J Cancer Res Clin Oncol; 2012 Jun; 138(6):959-69. PubMed ID: 22358301
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
14. Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes.
Lepelley P; Poulain S; Grardel N; Preudhomme C; Cosson A; Fenaux P
Leuk Lymphoma; 1998 May; 29(5-6):547-51. PubMed ID: 9643568
[TBL] [Abstract][Full Text] [Related]
15. In vitro drug sensitivity of leukemic progenitors and P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome.
Basara N; Radosević-Radojković N; Colović M; Bosković D; Rolović Z
Eur J Haematol; 1995 Aug; 55(2):83-7. PubMed ID: 7628594
[TBL] [Abstract][Full Text] [Related]
16. MDR1/P-GP expression as a prognostic factor in acute leukemias.
Marie JP; Legrand O
Adv Exp Med Biol; 1999; 457():1-9. PubMed ID: 10500774
[TBL] [Abstract][Full Text] [Related]
17. Management of acute myeloid leukemia in elderly patients.
Hiddemann W; Kern W; Schoch C; Fonatsch C; Heinecke A; Wörmann B; Büchner T
J Clin Oncol; 1999 Nov; 17(11):3569-76. PubMed ID: 10550156
[TBL] [Abstract][Full Text] [Related]
18. Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?
DeAngelo DJ; Stein EM; Ravandi F
Am Soc Clin Oncol Educ Book; 2016; 35():e302-12. PubMed ID: 27249736
[TBL] [Abstract][Full Text] [Related]
19. Both Pgp and MRP1 activities using calcein-AM contribute to drug resistance in AML.
Legrand O; Simonin G; Perrot JY; Zittoun R; Marie JP
Adv Exp Med Biol; 1999; 457():161-75. PubMed ID: 10500791
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
